Browsing Tag
phase 3 trial
22 posts
Padcev and Keytruda combo cuts bladder cancer recurrence risk by 60% in pivotal Phase 3 win
Discover how the Padcev and Keytruda combination achieved unprecedented survival gains in bladder cancer — read our expert take.
DXB rockets on Japan orphan drug win — can Dimerix finally deliver an FSGS breakthrough?
Dimerix (ASX: DXB) secures orphan drug designation in Japan for DMX-200, strengthening its global Phase 3 kidney trial program. Find out what’s next.
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission
Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.
Lilly’s oral GLP-1 drug orforglipron cuts A1C and body weight in type 2 diabetes Phase 3 trial
Eli Lilly’s once-daily oral GLP-1 therapy orforglipron delivered significant A1C and weight reductions in Phase 3 ACHIEVE-1 trial, with safety aligned to injectables.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
Lilly to expand into cardiovascular gene editing with Verve Therapeutics acquisition
Eli Lilly’s $1.3B acquisition of Verve Therapeutics targets breakthrough one-time gene therapies for high-risk cardiovascular patients. Read more.
Firebrick Pharma (ASX:FRE) surges as Nasodine Phase 3 trial confirms 40% cold relief
Firebrick Pharma’s Phase 3 Nasodine trial confirms 40% symptom relief in cold patients. Discover how this could accelerate global sales and investor interest.
Dimerix stock up 74% YTD as FSGS asset DMX-200 gets safety green light
Dimerix’s FSGS drug candidate DMX-200 clears key Phase 3 safety review with no concerns. Learn how this ASX biotech aims to reshape kidney disease treatment.